Lv52
950 积分 2022-08-16 加入
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
1天前
已完结
从临床数据解释细胞色素P-450抑制和诱导作用：当前标准和实施建议
4个月前
已完结
Nonclinical Efficacy and Toxicity and Selection of a Safe Clinical Starting Dose for an NMT Inhibitor in Development for Hematological Malignancies
5个月前
已关闭
Nonclinical Efficacy and Toxicity and Selection of a Safe Clinical Starting Dose for an NMT Inhibitor in Development for Hematological Malignancies
5个月前
已关闭
Scientific and Regulatory Policy Committee
5个月前
已完结
Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials
5个月前
已完结
Abstract PO3-18-06: First-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2- advanced/metastatic breast cancer (ABC) who progressed on prior CDK4/6 inhibitors (CDK4/6i)
6个月前
已完结
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
6个月前
已完结
Tumor-Agnostic Approvals: Insights and Practical Considerations
8个月前
已完结
Structural Biology of the Tumor Suppressor p53
8个月前
已完结
皖公网安备34019202002308
